Regenicin, Inc. (RGIN) Research

Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.

Market snapshot

Symbol
RGIN
Price
$0.00
Day change
0.00%
Market cap
$15.3K
P/E ratio
-0.02x
52-week range
0.0001-0.7501
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aeolus Pharmaceuticals, Inc. (AOLS)
  • NanoLogix, Inc. (NNLX)
  • Strategic Partners A/S (OZYMF)
  • Poniard Pharmaceuticals, Inc. (PARD)
  • Q BioMed Inc. (QBIO)
  • RenovaCare, Inc. (RCAR)
  • Scopus BioPharma Inc. (SCPS)
  • Vaxxinity, Inc. (VAXX)

Open Regenicin, Inc. (RGIN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.